These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7560661)

  • 41. Efficacy of inhaled formoterol in reversing bronchoconstriction.
    Rubin AS; Perin C; Pelegrin L; Fernandes JC; da Silva LC
    J Bras Pneumol; 2006; 32(3):202-6. PubMed ID: 17273608
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A study with cumulative doses of formoterol and salbutamol in children with asthma.
    Foucard T; Lönnerholm G
    Eur Respir J; 1991 Nov; 4(10):1174-7. PubMed ID: 1687130
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of treatment with formoterol on bronchoprotection against methacholine.
    Lipworth B; Tan S; Devlin M; Aiken T; Baker R; Hendrick D
    Am J Med; 1998 May; 104(5):431-8. PubMed ID: 9626025
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D; Vicaut E; Lefrançois G;
    Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study.
    Houghton CM; Langley SJ; Singh SD; Holden J; Monici Preti AP; Acerbi D; Poli G; Woodcock A
    Br J Clin Pharmacol; 2004 Oct; 58(4):359-66. PubMed ID: 15373928
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Bronchial asthma treated with long-acting beta 2 agonist. Comparison between formoterol (12 mu/g) inhaled twice daily and salbutamol (200 mu/g) inhaled 4 times daily].
    Sprogøe-Jakobsen U; Viktrup L; Davidsen O; Viskum K
    Ugeskr Laeger; 1992 Nov; 154(47):3325-8. PubMed ID: 1361083
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic equivalence of a novel HFA134a-containing metered-dose inhaler and the conventional CFC inhaler (Berodual) for the delivery of a fixed combination of fenoterol/ipratropium bromide. A randomized double-blind placebo-controlled crossover study in patients with asthma.
    Maesen FP; Greefhorst LP; Smeets JJ; Wald FD; Cornelissen PJ
    Respiration; 1997; 64(4):273-80. PubMed ID: 9257362
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients.
    Peters SP; Prenner BM; Mezzanotte WS; Martin P; O'Brien CD
    Allergy Asthma Proc; 2008; 29(5):499-516. PubMed ID: 18694544
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
    Busse W; Levine B; Andriano K; Lavecchia C; Yegen U
    Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Formoterol, a new long-acting bronchodilator for inhalation.
    Arvidsson P; Larsson S; Löfdahl CG; Melander B; Wåhlander L; Svedmyr N
    Eur Respir J; 1989 Apr; 2(4):325-30. PubMed ID: 2737271
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Studies on the bronchodilator, tremorogenic, cardiovascular and hypokalaemic effects of fenoterol dry powder in asthma.
    Bauer KG; Kaik B; Sertl K; Kaik GA
    Br J Clin Pharmacol; 1993 Oct; 36(4):285-92. PubMed ID: 12959305
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The safety and clinical benefit of budesonide/formoterol pressurized metered-dose inhaler versus budesonide alone in children.
    Berger WE; Leflein JG; Geller DE; Parasuraman B; Miller CJ; O'Brien CD; O'Dowd L
    Allergy Asthma Proc; 2010; 31(1):26-39. PubMed ID: 20167143
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients.
    Rosenborg J; Larsson P; Rott Z; Böcskei C; Poczi M; Juhász G
    Eur J Clin Pharmacol; 2002 Jul; 58(4):S61-7. PubMed ID: 12214580
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety.
    Bodzenta-Lukaszyk A; Buhl R; Balint B; Lomax M; Spooner K; Dissanayake S
    J Asthma; 2012 Dec; 49(10):1060-70. PubMed ID: 23102189
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A single dose comparison of a combination of fenoterol and ipratropium aerosols in bronchial asthma.
    Lawford P; Palmer KN
    Postgrad Med J; 1983 Jan; 59(687):28-30. PubMed ID: 6223289
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the effects of salmeterol and formoterol in patients with severe asthma.
    Nightingale JA; Rogers DF; Barnes PJ
    Chest; 2002 May; 121(5):1401-6. PubMed ID: 12006420
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Changes in specific airway resistance after powder inhalation of formoterol or salmeterol in moderate bronchial asthma].
    Sill V; Bartuschka B; Villiger B; Ortland C; Domej W
    Pneumologie; 1999 Jan; 53(1):4-9. PubMed ID: 10091511
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma.
    Kruse M; Rosenkranz B; Dobson C; Ayre G; Horowitz A
    Pulm Pharmacol Ther; 2005; 18(3):229-34. PubMed ID: 15707858
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bronchoprotective and bronchodilator effects of an HFA pMDI vs. a CFC pMDI and a DPI containing formoterol in asthma patients.
    Langley SJ; Houghton CM; Singh SD
    Respiration; 2005; 72 Suppl 1():35-7. PubMed ID: 15915011
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration.
    Lipworth BJ; Aziz I
    Chest; 2000 Jan; 117(1):156-62. PubMed ID: 10631214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.